Basic Information
| LncRNA/CircRNA Name | RP11-838N2.4 |
| Synonyms | NA |
| Region | GRCh38_18:3466250-3478978 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | erlotinib | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | Microarray, qPCR, Western blot etc. |
| Sample | non small cell lung cancer tissues, serum, cell lines (HCC827 and HCC4006) |
| Expression Pattern | up-regulated |
| Function Description | In addition, the serum expression levels of exosomal lncRNA RP11-838N2.4 were upregulated in patients exhibiting resistance to erlotinib treatment. On the whole, exosomal lncRNA RP11-838N2.4 may serve as a therapeutic target for patients with NSCLC. |
| Pubmed ID | 29845246 |
| Year | 2018 |
| Title | Exosome-mediated transfer of lncRNA RP11-838N2.4 promotes erlotinib resistance in non-small cell lung cancer |
External Links
| Links for RP11-838N2.4 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |